Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder

This open-label single-group Phase II study evaluated repeated IV ketamine (0.5 mg/kg weekly for four infusions) combined with a single IM naltrexone 380 mg injection in participants with major depressive disorder and comorbid alcohol use disorder.

Primary objectives were to assess rapid antidepressant effects and changes in alcohol consumption; safety and tolerability were monitored throughout the treatment course.